Online Corrigendum

Abstract

Morrill, A.M., Ge, D. & Willett, K.C. Dosing of Target-Specific Oral Anticoagulants in Special Populations. Ann Pharmacother. 2015;49:1031-1045. (Original doi: 10.1177/1060028015591846)

In Table 1 on page 1033 of the above article, in the dosing recommendation section for dabigatran (4th and 5th column), there is a sentence which reads: Treatment of VTE “150 mg daily for 5-10 days, then 150 mg BID” and “Renal: Avoid if CrCl <50 mL/min”

This sentence should have read: “150 mg BID” and “Renal: Avoid if CrCl <30 mL/min” respectively.